Immunic Announces Promising Vidofludimus Calcium Data at MSToronto2026
Immunic, Inc., a leading late-stage biotechnology firm specializing in innovative oral therapies for neurologic conditions, is set to present four pivotal abstracts focusing on their investigational drug, vidofludimus calcium, during the impending MSToronto2026 event. Scheduled for October 21-23, 2026, this tenth Joint ACTRIMS-ECTRIMS Meeting in Toronto, Canada will serve as a crucial platform for discussing advancements in multiple sclerosis (MS) treatment.
These accepted abstracts will incorporate novel clinical, biomarker, and preclinical insights that showcase the unique profile of vidofludimus calcium aimed at tackling various aspects of MS. The event's materials will also be made available as an online supplement through the Multiple Sclerosis Journal and the conference’s digital resources. Immunic's team will maintain a presence at booth #516, ready to engage with other professionals in the field.
Erik Lundgren, CEO of Immunic, highlighted the importance of the findings that will be showcased. He stated that these presentations will contribute significantly to the understanding of vidofludimus calcium among the broader MS community, emphasizing both the drug's potential ability to manage inflammatory disease activity and lessen disability progression.
1. Evaluation of Long-term Disability Outcomes
- Lead Author: Robert J. Fox, M.D., of the Cleveland Clinic.
- Session: Poster Session 1, Wednesday, October 21, 2026.
- This study evaluates the disability outcomes from an open-label extension of a Phase 2 trial, revealing encouraging results for those consistently receiving vidofludimus calcium compared to those who transitioned from a placebo. The findings discussed include a reduced risk of long-term disability worsening and increased instances of recovery.
2. Investigating Nurr1's Role in Neuronal Survival
- Lead Author: Mehrnoosh Jafari, Senior Manager at Immunic.
- Session: Poster Session 2, Thursday, October 22, 2026.
- The research presented examines how vidofludimus calcium promotes neuronal survival, identifying that its protective effects are dependent on Nurr1. Furthermore, it reports how the drug mitigates microglia-driven neuronal damage in a preclinical setting.
3. Correlation Between EBV Activity and Cognitive Performance
- Lead Author: Amelie Schreieck, Ph.D.
- Session: ePosters displayed throughout the congress duration.
- This analysis from the CALLIPER trial denotes that reductions in Epstein-Barr virus (EBV) specific T-cell receptor signatures correlate with improved cognitive performance among patients with progressive MS, particularly notable in those with primary progressive MS.
4. New Endpoint Proposals for Disability Changes in MS
- Lead Author: James Myles, Global Head of Biostatistics at Immunic.
- Session: ePosters available for the duration of the congress.
- This research suggests a novel endpoint for measuring treatment efficacy, combining disability worsening and improvement into a single analytic framework, presenting compelling statistics that encourage further investigation into this method.
Immunic’s primary project, vidofludimus calcium (IMU-838), is under investigation in ongoing Phase 3 trials for relapsing multiple sclerosis, with results anticipated by the end of 2026. Additionally, a second Phase 3 trial targeting progressive MS is projected to commence later this year. Notably, vidofludimus calcium has demonstrated a promising safety and tolerability profile in previous trials, leading to optimism regarding its potential as a neuroprotective and anti-inflammatory agent. Alongside this compound, Immunic offers a pipeline of early-stage projects aimed at addressing a range of neurodegenerative and autoimmune disorders. For more information, visit www.imux.com.
Caution: Vidofludimus calcium remains an investigational product, and it has yet to receive approval from key regulatory bodies such as the FDA and EMA. The associated clinical data currently available should not be interpreted as evidence of safety or efficacy.
These accepted abstracts will incorporate novel clinical, biomarker, and preclinical insights that showcase the unique profile of vidofludimus calcium aimed at tackling various aspects of MS. The event's materials will also be made available as an online supplement through the Multiple Sclerosis Journal and the conference’s digital resources. Immunic's team will maintain a presence at booth #516, ready to engage with other professionals in the field.
Erik Lundgren, CEO of Immunic, highlighted the importance of the findings that will be showcased. He stated that these presentations will contribute significantly to the understanding of vidofludimus calcium among the broader MS community, emphasizing both the drug's potential ability to manage inflammatory disease activity and lessen disability progression.
Highlights of the Presentations
1. Evaluation of Long-term Disability Outcomes
- Lead Author: Robert J. Fox, M.D., of the Cleveland Clinic.
- Session: Poster Session 1, Wednesday, October 21, 2026.
- This study evaluates the disability outcomes from an open-label extension of a Phase 2 trial, revealing encouraging results for those consistently receiving vidofludimus calcium compared to those who transitioned from a placebo. The findings discussed include a reduced risk of long-term disability worsening and increased instances of recovery.
2. Investigating Nurr1's Role in Neuronal Survival
- Lead Author: Mehrnoosh Jafari, Senior Manager at Immunic.
- Session: Poster Session 2, Thursday, October 22, 2026.
- The research presented examines how vidofludimus calcium promotes neuronal survival, identifying that its protective effects are dependent on Nurr1. Furthermore, it reports how the drug mitigates microglia-driven neuronal damage in a preclinical setting.
3. Correlation Between EBV Activity and Cognitive Performance
- Lead Author: Amelie Schreieck, Ph.D.
- Session: ePosters displayed throughout the congress duration.
- This analysis from the CALLIPER trial denotes that reductions in Epstein-Barr virus (EBV) specific T-cell receptor signatures correlate with improved cognitive performance among patients with progressive MS, particularly notable in those with primary progressive MS.
4. New Endpoint Proposals for Disability Changes in MS
- Lead Author: James Myles, Global Head of Biostatistics at Immunic.
- Session: ePosters available for the duration of the congress.
- This research suggests a novel endpoint for measuring treatment efficacy, combining disability worsening and improvement into a single analytic framework, presenting compelling statistics that encourage further investigation into this method.
About Immunic, Inc.
Immunic’s primary project, vidofludimus calcium (IMU-838), is under investigation in ongoing Phase 3 trials for relapsing multiple sclerosis, with results anticipated by the end of 2026. Additionally, a second Phase 3 trial targeting progressive MS is projected to commence later this year. Notably, vidofludimus calcium has demonstrated a promising safety and tolerability profile in previous trials, leading to optimism regarding its potential as a neuroprotective and anti-inflammatory agent. Alongside this compound, Immunic offers a pipeline of early-stage projects aimed at addressing a range of neurodegenerative and autoimmune disorders. For more information, visit www.imux.com.
Caution: Vidofludimus calcium remains an investigational product, and it has yet to receive approval from key regulatory bodies such as the FDA and EMA. The associated clinical data currently available should not be interpreted as evidence of safety or efficacy.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.